Bavarian Nordic A/S has announced that Health Canada has accepted its New Drug Submission for the review of its chikungunya vaccine candidate, CHIKV VLP. This marks a significant step in the company's efforts to expand global access to the vaccine, which has already received approvals in the US, EU, and UK. The submission is based on data from two successful phase 3 clinical trials involving over 3,500 participants, demonstrating high efficacy and safety. Pending approval, the vaccine could become available to Canadians seeking protection against chikungunya virus as early as the first half of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.